Coronavirus: Pfizer reports encouraging, very early COVID-19 vaccine test results

Researchers work on a potential vaccine for the coronavirus disease (COVID-19) at Pfizer’s laboratory in Pearl River, New York, US. (Reuters)

The first of four experimental COVID-19 vaccines being tested by Pfizer and its German partner BioNTech showed encouraging results in very early testing of 45 people, the companies said Wednesday.

Study volunteers given either a low or medium dose, in two shots about a month apart, had immune responses in the range expected to be protective, when compared to some COVID-19 survivors, according to the preliminary results.

Side effects were typical for vaccines, mostly pain at the injection site and fever.

For more coronavirus news, visit our dedicated page.

The report has been submitted for publication in a scientific journal but not yet reviewed. With its other potential candidates still in the earliest stage of testing, Pfizer aims to open a large-scale study this summer but can’t yet say which shot is best to include.

Read more:

Oxford’s potential COVID-19 vaccine shows ‘right sort of immune response’: Scientist

Number of daily new coronavirus cases exceeded 160,000 every day the past week: WHO

But researchers didn’t administer a second shot of the highest dose initially tested, sticking with the low and medium doses. The higher-dose shot caused more injection reactions without apparent added benefit.

For all the latest headlines follow our Google News channel online or via the app.

About 15 different COVID-19 vaccine candidates are in human testing worldwide, with several poised to begin huge, last-stage studies to prove if they really work.

Different companies are pursuing different types of vaccines, boosting the odds that at least one approach might work — although there’s no guarantee. The Pfizer and BioNTech candidates use a piece of the coronavirus genetic code to prime the body to recognize and attack the virus.

Earlier this week, Inovio Pharmaceuticals issued a news release saying its gene-based vaccine candidate showed encouraging results in similar early testing in 40 volunteers.

SHOW MORE
Last Update: Thursday, 02 July 2020 KSA 23:47 - GMT 20:47
Top